Vertex Pharmaceuticals Inc - Company Profile

Powered by

All the data and insights you need on Vertex Pharmaceuticals Inc in one report.

  • Save hours of research time and resources with
    our up-to-date Vertex Pharmaceuticals Inc Strategy Report

  • Understand Vertex Pharmaceuticals Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Vertex Pharmaceuticals Inc: Overview

Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that discovers, develops and commercializes transformative drugs for the treatment of serious and life-threatening diseases. The company’s product portfolio includes Trikafta, Symdeko/Symkevi, Orkambi (ivacaftor/lumacaftor), and Kalydeco (ivacaftor) for the treatment of cystic fibrosis. Through its research and development efforts, the company focuses on cystic fibrosis, sickle cell diseases, beta thalassemia, type-1 diabetes and pain. It uses state-of-the-art technology platforms to discover new disease targets, compounds, delivery mechanisms, and treatment modalities. Vertex has R&D centers and commercial offices in North America, South America, Europe, and Australia. The company offers its products in the US, Europe, Australia, and Canada. Vertex is headquartered in Boston, Massachusetts, the US.

Gain a 360-degree view of Vertex Pharmaceuticals Inc and make more informed decisions for your business Gain a 360-degree view of Vertex Pharmaceuticals Inc and make more informed decisions for your business Find out more
Headquarters United States of America

Address 50 Northern Avenue, Boston, Massachusetts, 02210


Telephone 1 617 3416100

No of Employees 5,400

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange VRTX (NASD)

Revenue (2022) $9.9B 10.5% (2022 vs 2021)

EPS XYZ

Net Income (2022) XYZ 9% (2022 vs 2021)

Market Cap* $103.4B

Net Profit Margin (2022) XYZ -1.4% (2022 vs 2021)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Vertex Pharmaceuticals Inc premium industry data and analytics

340+

Clinical Trials

Determine Vertex Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

210+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Vertex Pharmaceuticals Inc’s relevant decision makers and contact details.

180+

Catalyst Calendar

Proactively evaluate Vertex Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

130+

Pipeline Drugs

Identify which of Vertex Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

100+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

17+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

10+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Vertex Pharmaceuticals Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

5

Marketed Drugs

Understand Vertex Pharmaceuticals Inc’s commercialized product portfolio to stay one step ahead of the market.

1

Investigators

Review investigator profiles and find information on trial contacts across Vertex Pharmaceuticals Inc, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Vertex Pharmaceuticals Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products
Trikafta - Cystic Fibrosis
Symdeko/Symkevi - Cystic Fibrosis
Orkambi - Cystic Fibrosis
XYZ
XYZ
XYZ
Understand Vertex Pharmaceuticals Inc portfolio and identify potential areas for collaboration Understand Vertex Pharmaceuticals Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Others In April, the company announced the advancement of inaxaplin (VX-147) into the Phase III segment of the global Phase II/III pivotal trial for APOL1-mediated kidney disease.
2024 Regulatory Approval In March, the company received approval from the U.S. Food and Drug Administration for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease in patients with a subset of PKD1 genetic variants.
2024 Regulatory Approval In January, the company received approval for CASGEVY (exagamglogene autotemcel) to treat sickle cell disease and transfusion-dependent beta-thalassaemia in patients aged 12 and above.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Vertex Pharmaceuticals Inc AbbVie Inc Novartis AG Arcturus Therapeutics Holdings Inc Krystal Biotech Inc
Headquarters United States of America United States of America Switzerland United States of America United States of America
City Boston North Chicago Basel San Diego Pittsburgh
State/Province Massachusetts Illinois - California Pennsylvania
No. of Employees 5,400 50,000 76,057 180 229
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Jeffrey M. Leiden, M.D., Ph.D. Chairman Executive Board 2020 67
Reshma Kewalramani, M.D. Chief Executive Officer; Director; President Executive Board 2020 50
Charles F. Wagner Chief Financial Officer; Executive Vice President Senior Management 2019 54
Stuart A. Arbuckle Chief Operating Officer; Executive Vice President Senior Management 2021 57
Kristen C. Ambrose Chief Accounting Officer; Senior Vice President Senior Management 2021 46
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Vertex Pharmaceuticals Inc key executives to enhance your sales strategy Gain insight into Vertex Pharmaceuticals Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward